9 June 2017:link here
Adherium Limited (ASX : ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of Arik Anderson as Group Chief Executive Officer (CEO). Founder and past Group CEO, Garth Sutherland, welcomed the appointment of Arik as a key step in the next and important phase of Adherium’s global business growth, allowing him to focus on new areas of development while Mr Anderson focusses on the global business opportunities in front of the Company today. This transition of control at the top of the Company is a very considered step by the Board and as a key part of the transition Mr Sutherland, in the interim, will remain an Executive Director on the Adherium Board.
With over 25 years of experience in the medical technology and medical device manufacturing industries, Mr Anderson has led significant growth for emerging technology companies. Most recently, Mr Anderson was President of Perfusion and Surgical Devices at Terumo Cardiovascular Systems (TYO: 4543), responsible for a US$300M portfolio of devices used in the surgical operating room which was sold in more than 170 countries. Previously, he was Senior Vice President, R&D and Operations, and General Manager at Somanetics (NASDAQ: SMTS) from 2007 until the company’s integration with Covidien was completed in 2011.
Mr Anderson has also served as Director of Product Development at Delphi Medical Systems (NYSE: DLPH), a provider of technology and products to the infusion, respiratory care, vital signs monitoring and power mobility medical device markets. In addition, he was President and Chief Executive Officer of Tasso Solutions, a product development and manufacturing consulting firm. Mr Anderson retains Board positions on the University of Michigan Medical School MTRAC Board, which oversees investment in medical technology, and the University of Michigan Ross School of Business Zell Lurie Healthcare Board which oversees student investment in emerging technology via the Zell Lurie Commercialization Fund.
Mr Sutherland, Adherium Founder said: “Adherium is very fortunate to attract someone of Arik’s standing, he is ideally suited to lead the company into its commercial growth phase as we focus on expanding our global footprint. We welcome him to our team, his industry experience, combined with our award-winning Smartinhaler™ products and technology platform, will allow Adherium to further build upon its position as a market leader in the digital health space. His arrival will also allow me more time to focus on areas of new product development that I have been wanting to undertake for some time now.”
Mr Anderson, Adherium’s new CEO, said: "Adherium’s digital health solutions are already having a positive impact on the health of people with respiratory disease globally. I look forward to leading the organization to bring the benefits of Smartinhaler™ to patients world-wide.”
Tom Lynch, Adherium Chairman, said: “Arik will be a strong leader for our business arriving at a key time as our products and services experience significant and rising global demand.”
Mr Anderson assumes the role of Group CEO immediately and will be based at Adherium’s U.S. headquarters in San Mateo, CA. He holds a Bachelor of Science degree in Electrical and Computer Engineering from the University of Wisconsin, Madison.